Almorexant is primarily studied for its potential application in the treatment of insomnia. It functions as a dual orexin receptor antagonist, targeting the orexin system, which plays a key role in regulating wakefulness and sleep. By blocking orexin receptors, it promotes sleep initiation and maintenance, offering a novel approach compared to traditional sedative-hypnotics. Its mechanism of action is considered to be more physiological, as it works by modulating the natural sleep-wake cycle rather than inducing sedation through generalized central nervous system depression. Clinical trials have explored its efficacy in improving sleep onset and duration, with a focus on minimizing next-day residual effects. However, its development has faced challenges, and it is not widely approved or marketed for therapeutic use. Research continues to evaluate its potential benefits and safety profile in sleep disorders.